Agents that promote or maintain histone acetylation through HDAC inhibition and/or HAT stimulation may help to lower colon adenoma/carcinoma incidence, especially in high-risk families, or could be included in therapeutic protocols to treat advanced colon cancer. Here, HDAC9 is linked to colonic neoplasm.